Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study

Basit Öğe Kaydı
dc.authorid0000-0002-2242-9401en_US
dc.authorid0000-0002-1729-2834en_US
dc.contributor.authorKurtoğlu, Selim
dc.contributor.authorAtabek, Mehmet Emre
dc.contributor.authorDizdarer, Ceyhun
dc.contributor.authorPirgon, Mustafa Özgür
dc.contributor.authorİşgüven, Pınar
dc.contributor.authorEmek, Sevil
dc.date.accessioned2024-07-12T21:10:40Z
dc.date.available2024-07-12T21:10:40Z
dc.date.issued2009en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractBackground: Insulin detemir is a basal insulin analog designed to produce a superior pharmacokinetic profile to basal formulations of human insulin. It has shown consistently improved tolerability in comparison to neutral protamine Hagedorn (NPH) insulin in adult cohorts, but there are relatively few publications involving pediatric cohorts. Methods: The efficacy and safety of insulin detemir in children with type 1 diabetes was assessed using data from the Turkish cohort of PREDICTIVE (a large, multinational, observational) study. The children investigated were using basal-bolus therapy involving NPH insulin or insulin glargine at baseline but were switched to insulin detemir as part of routine clinical care by their physicians. Results: Twelve weeks of treatment with insulin detemir significantly reduced mean hemoglobin A1c (9.7-8.9%, p < 0.001) and mean fasting glucose [185-162 mg/dL (10.3-9 mmol/L), p < 0.01]. Fasting glucose variability was also lower after treatment with insulin detemir than previously (on either NPH or glargine, p < 0.05). The frequencies of total, major and nocturnal hypoglycemic events were significantly reduced with insulin detemir relative to baseline, with an estimated mean of 6.89 fewer events/patient/yr overall (p < 0.001) and 2.6 fewer nocturnal events/patient/yr (p < 0.01). Weight and insulin dose remained relatively unchanged. Conclusions: Twelve weeks of treatment with insulin detemir improved glycemic control and reduced hypoglycemia in children with type 1 diabetes. This improved tolerability might allow further dose titration and therefore additional improvements in glucose control.en_US
dc.identifier.citationKurtoğlu, S., Atabek, M.E., Dizdarer, C., Pirgon, O., İşgüven, P. ve Emek, S. (2009). PREDICTIVE Turkey Study Group. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study. Pediatric Diabetes, Wiley. 10(6), s. 401-407.en_US
dc.identifier.endpage407en_US
dc.identifier.issn1399-5448
dc.identifier.issue6en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage401en_US
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/19220776/
dc.identifier.urihttps://hdl.handle.net/20.500.12415/4272
dc.identifier.volume10en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatric Diabetesen_US
dc.relation.isversionof10.1111/j.1399-5448.2008.00497.xen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY03218
dc.subjectdiabetes mellitus type 1en_US
dc.subjecthypoglycemiaen_US
dc.subjectinsulin detemiren_US
dc.subjectpediatricen_US
dc.titleInsulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational studyen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu